Sinopharm Group Co Ltd
01099: XHKG (HKG)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
HK$76.40 | Qzwbdq | Klbcyhlvq |
Sinopharm's Full-Year Results in Line, Shares Remain Attractive
Narrow-moat Sinopharm’s full-year 2021 revenue was in line with our expectations. Full-year revenue was CNY 508 million, growing at 14% year on year and just 2% higher than our forecast. Our fair value estimate is unchanged at HKD 29.50 per share, and shares are 38% undervalued relative to this.